Program Faculty.................................................................1
Sponsorship and CME Credit..................................................2
CME Activity Assessment and Evaluation..............................4

Novel Agents in the Treatment of Lung Cancer: Fourth Cambridge Conference

Erlotinib: Recent Clinical Results and Ongoing Studies in Non–Small Cell Lung Cancer
Roman Perez-Soler...........................................................................4589s

HKI-272 in Non–Small Cell Lung Cancer
Kwok-Kin Wong..............................................................................4593s

Antibodies to the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer: Current Status of Matuzumab and Panitumumab
Mark A. Socinski ...........................................................................4597s

Is There a Role for Cetuximab in Non–Small Cell Lung Cancer?
Daniel Morgensztern and Ramaswamy Govindan ..................................4602s

Selecting Patients for Treatment with Epidermal Growth Factor Tyrosine Kinase Inhibitors
Philip D. Bonomi, Lela Buckingham, and John Coon..................................4606s

Bevacizumab in Non–Small Cell Lung Cancer
Alan Sandler ...........................................................................4613s

Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors Vandetanib (ZD6474) and AZD2171 in Lung Cancer
Emer O. Hanrahan and John V. Heymach............................................4617s

Vascular Endothelial Growth Factor Trap in Non–Small Cell Lung Cancer
Gregory J. Riely and Vincent A. Miller.............................................4623s

Rationale for a Phase I Trial of Erlotinib and the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) for Patients with Relapsed Non–Small Cell Lung Cancer
Bruce E. Johnson, David Jackman, and Pasi A. Jänne.................................4628s

Antagonism of Platelet-Derived Growth Factor Receptor in Non–Small Cell Lung Cancer: Rationale and Investigations
Julie E. Bauman, Keith D. Eaton, and Renato G. Martins..............................4632s

The Role of Phosphoinositide 3-Kinase Pathway Inhibitors in the Treatment of Lung Cancer
Jeffrey A. Engelman ...........................................................................4637s

Enzastaurin, a Protein Kinase Cβ-Selective Inhibitor, and Its Potential Application as an Anticancer Agent in Lung Cancer
Roy S. Herbst, Yun Oh, Asavari Wagle, and Michael Lahn.............................4641s

Incorporating Bortezomib into the Treatment of Lung Cancer
Angela M. Davies, Primo N. Lara, Jr., Philip C. Mack, and David R. Gandara.................................................................4647s

L-BLP25: A Peptide Vaccine Strategy in Non–Small Cell Lung Cancer
Randeep Sangha and Charles Butts ........................................................4652s